Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.
about
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaApplication of quantitative pharmacology in development of therapeutic monoclonal antibodiesPharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.The influence of antibody fragment format on phage display based affinity maturation of IgG.Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.Clinical trial simulation: a review.Prediction of exposure-response relationships to support first-in-human study design.Engineering the variable region of therapeutic IgG antibodies.The current role of model-based drug development.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.Structure of the omalizumab Fab.Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments.Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.
P2860
Q27689386-0351F133-2F66-4556-81AE-8675DAB01CC9Q34293689-7EA5F79E-8714-478A-B976-1669F8FBD8F0Q34782224-FB06C673-0F1B-4781-8056-17B677549F43Q34901024-E2DBDE4D-C5E9-45AE-B7FB-50364616318BQ35050036-8A9BBB86-90A0-4AA8-8DFC-8DB7250DD885Q36951905-B4A9BC68-FA6F-473D-9CF1-9DAC4E0F5A0EQ37161497-D7A7C618-52D5-4853-BDC0-1D2DB1063845Q37635011-AB202359-7CB3-4264-8DA7-140C62D27D43Q37770955-A63AE206-8AC7-46EF-8901-4F298023EB9AQ37802266-E6548378-B937-4DDE-8E23-44D43F44ABBCQ37853324-6ECA885B-2519-4AB8-9E89-F2C1532BAB89Q38028538-BBC4CCCD-69B3-433C-83E7-E798B9483F08Q38072598-80F86604-7DA5-4623-A06C-6441E8B89157Q38364466-A9BA54A7-86AB-4255-9C82-74CAE0ABE80CQ38396322-2DB78CC6-130B-482E-ADD0-47D06DCEE2C3Q38856152-6CC6771E-A561-4643-B2E8-67AE6322DD39Q39335284-50559D7E-0DBE-4D03-845D-3FBD72E973F7Q41575242-958EB079-0AE5-4158-9C40-56331FE436FEQ41787797-2C43FCA9-41F9-424C-86DE-635FE18F89CFQ41807110-9CE09BA2-03A5-4391-9875-242B070CE417Q41867620-B9C34B50-6626-4F2C-A5BD-5A5B90F5127BQ51570078-7CDB1BD3-3CFD-413A-B09F-5667EA806155Q51768954-6F93B57F-D679-4163-8F82-8B91749C0725
P2860
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@ast
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@en
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@nl
type
label
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@ast
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@en
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@nl
prefLabel
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@ast
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@en
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@nl
P2093
P2860
P1433
P1476
Use of quantitative pharmacolo ...... anti-IgE monoclonal antibody.
@en
P2093
Amita Joshi
Henry Lowman
Jennifer Visich
Jonas Haggstrom
Melissa Cheu
Nelson Shasha Jumbe
Paul Fielder
Saloumeh Kadkhodayan-Fischer
P2860
P2888
P304
P356
10.1208/S12248-008-9045-4
P407
P577
2008-06-01T00:00:00Z
P5875
P6179
1024421016